Published on
January 21, 2026
- 18:28 GMT
REACX PHARMACEUTICALS NALMEFENE PHASE 1 CLINICAL STUDY
SOUTH SAN FRANCISCO, CA, UNITED STATES, January 21, 2026 /EINPresswire.com/ -- ReacX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the development of long-term treatments for substance use disorders, today announced the …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
